ribavirin has been researched along with lomibuvir in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Alves, K; Asmal, M; DeSouza, C; Di Bisceglie, AM; Gane, E; George, S; Jacobson, IM; Kauffman, R; Kieffer, T; Koziel, MJ; Nelson, D; Sulkowski, M; Zhang, EZ | 1 |
1 trial(s) available for ribavirin and lomibuvir
| Article | Year |
|---|---|
VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cyclohexanols; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thiophenes; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2014 |
1 other study(ies) available for ribavirin and lomibuvir
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |